Group items matching

in title, tags, annotations or url

The global Intravenous Solutions Market size is expected to reach USD 18.9 billion by 2028 according to a new report

Piramal Critical Care is a business unit of Piramal Healthcare Limited. It manufactures and exports an extensive range of inhalation anesthetics like Sevoflurane, Halothane, Isoflurane and Enflurane, intravenous anesthetics like Propofol, regional anesthetics like Bupivacaine, muscle relaxants like Atracurium and plasma volume expanders like Polygeline.

Pseudomonas aeruginosa is a very common cause of endocarditis,specially in intravenous drug users.It has the capacity to infect native as well as prosthetic heart valves.The source of this bacteria is usually the standing water contaminating drug

Hey Dear Check Out Our Online Shopping store in all Over Pakistan.As Seen as On Tv Products Like as Health Beauty,Fitness,Homeware,Kitchenware,And Other Electronic Products in Pakistan Check Out Now| www.openTeleshop.Com

Tadalista 20 mg https://www.mymedistore.com/product/tadalista-20-mg/ Mymedistore provide Tadalista 5mg ,Tadalista 10 mg ,Tadalista 20 mg product services at across the USA countries with affordable price rate.

Propovan (Propofol Injection) is a short acting intravenous anesthetic agent used for induction and maintenance of general anesthesia. Chemically unrelated to other anesthetics it is not only used in adult and pediatric patients but also used as a veterinary medicine.

Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report. Demand also has been hampered by the perception that Omicron infections are not that severe. Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial. Thousands of people still die from Covid-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.

UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."

Great news for multiple sclerosis patients! The NHS has introduced a new 10-minute injection that can slow the progression of disability while reducing hospital treatment time by over 90 per cent. Currently, MS patients in England receive ocrelizumab (Ocrevus), manufactured by Roche, through twice-yearly intravenous (IV) infusions that can last up to four hours. Now, around 9,000 NHS patients in England will be able to receive the drug via a quick 'under-the-skin' twice-yearly injection. It takes just ten minutes, enabling patients to spend less time in the hospital receiving treatment. This roll-out follows approval from the Medicines and Healthcare products Regulatory Agency (MHRA), making the NHS one of the first healthcare systems worldwide to offer this new MS injection. Drug stocks are expected to be available in the coming weeks.

A new cancer treatment for adults with stomach (gastric) and gastro oesophageal junction cancer has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) this week. According to the MHRA, Zolbetuximab, a monoclonal antibody, is designed to target and destroy specific cancer cells, offering a new option for patients whose cancer is inoperable or has spread. The new targeted cancer treatment for gastric and gastro-oesophageal junction cancer is administered intravenously in combination with standard chemotherapy regimens and is typically given every two to three weeks under the supervision of an experienced oncologist. Zolbetuximab is indicated for patients whose tumors are positive for the Claudin18.2 (CLDN18.2) protein and negative for the Human epidermal growth factor receptor 2 (HER2) protein.

The US Food & Drug Administration (FDA) has granted fast track designations for both the intravenous (IV) and oral formulations of Tetraphase Pharmaceuticals' lead antibiotic candidate, eravacycline.

MANGAFODIPIR is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. The contrast agent is present as mangafodipir trisodium marketed under the name TESLASCAN.